Miriam K Laufer

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. pmc Gestational age assessment in malaria pregnancy cohorts: a prospective ultrasound demonstration project in Malawi
    Blair J Wylie
    Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Malar J 12:183. 2013
  2. pmc A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria
    Miriam K Laufer
    Malaria Group, Howard Hughes Medical Institute Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 7:e42284. 2012
  3. pmc World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs
    Ric N Price
    International Health Program, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia
    Malar J 6:119. 2007
  4. pmc Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites
    Miriam K Laufer
    Center for Vaccine Development, University of Maryland School of Medicine, 685 W Baltimore Street, Baltimore, MD 21201, USA
    J Infect Dis 202:801-8. 2010
  5. pmc Monitoring antimalarial drug efficacy: current challenges
    Miriam K Laufer
    Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA
    Curr Infect Dis Rep 11:59-65. 2009
  6. ncbi request reprint Monitoring and deterring drug-resistant malaria in the era of combination therapy
    Miriam K Laufer
    Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, 685 W Baltimore Street, Baltimore, MD 21201, USA
    Am J Trop Med Hyg 77:160-9. 2007
  7. ncbi request reprint Malaria treatment efficacy among people living with HIV: the role of host and parasite factors
    Miriam K Laufer
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Am J Trop Med Hyg 77:627-32. 2007
  8. ncbi request reprint Return of chloroquine antimalarial efficacy in Malawi
    Miriam K Laufer
    University of Maryland School of Medicine, Baltimore, MD 21201, USA
    N Engl J Med 355:1959-66. 2006
  9. ncbi request reprint Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi
    Miriam K Laufer
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, USA
    J Infect Dis 193:872-8. 2006
  10. pmc Clinical manifestations of new versus recrudescent malaria infections following anti-malarial drug treatment
    Ayesha M Shaukat
    Malaria Group, Howard Hughes Medical Institute Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    Malar J 11:207. 2012

Research Grants

  1. Molecular epidemiology of drug resistant malaria
    MIRIAM LAUFER; Fiscal Year: 2007

Collaborators

Detail Information

Publications17

  1. pmc Gestational age assessment in malaria pregnancy cohorts: a prospective ultrasound demonstration project in Malawi
    Blair J Wylie
    Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Malar J 12:183. 2013
    ..Where ultrasound is accessible, sonographic confirmation of gestational age is more accurate than menstrual dating. The goal was to pilot the feasibility and utility of adding ultrasound to an observational pregnancy malaria cohort...
  2. pmc A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria
    Miriam K Laufer
    Malaria Group, Howard Hughes Medical Institute Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 7:e42284. 2012
    ..We aimed to compare the ability of different partner drugs to preserve chloroquine efficacy and prevent the re-emergence of resistance...
  3. pmc World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs
    Ric N Price
    International Health Program, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia
    Malar J 6:119. 2007
    ..This resource will help guide rational drug policies that optimize antimalarial drug use, in the hope that the emergence and spread of resistance to new drugs can be, if not prevented, at least delayed...
  4. pmc Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites
    Miriam K Laufer
    Center for Vaccine Development, University of Maryland School of Medicine, 685 W Baltimore Street, Baltimore, MD 21201, USA
    J Infect Dis 202:801-8. 2010
    ..Chloroquine-susceptible parasites that predominate in Malawi likely represent a reexpansion of the susceptible parasites that survived in the population despite widespread drug pressure in the region...
  5. pmc Monitoring antimalarial drug efficacy: current challenges
    Miriam K Laufer
    Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA
    Curr Infect Dis Rep 11:59-65. 2009
    ..This review discusses the challenges to various methods to monitor antimalarial drug resistance and proposes an integrated approach to the rapid detection and characterization of resistance to ACTs should it arise...
  6. ncbi request reprint Monitoring and deterring drug-resistant malaria in the era of combination therapy
    Miriam K Laufer
    Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, 685 W Baltimore Street, Baltimore, MD 21201, USA
    Am J Trop Med Hyg 77:160-9. 2007
    ..The malaria research and control community should not fail to exploit this opportunity to apply the lessons of the last 50 years to extend the useful therapeutic lives of ACTs...
  7. ncbi request reprint Malaria treatment efficacy among people living with HIV: the role of host and parasite factors
    Miriam K Laufer
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Am J Trop Med Hyg 77:627-32. 2007
    ....
  8. ncbi request reprint Return of chloroquine antimalarial efficacy in Malawi
    Miriam K Laufer
    University of Maryland School of Medicine, Baltimore, MD 21201, USA
    N Engl J Med 355:1959-66. 2006
    ..The molecular marker of chloroquine-resistant falciparum malaria subsequently declined in prevalence and was undetectable by 2001, suggesting that chloroquine might once again be effective in Malawi...
  9. ncbi request reprint Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi
    Miriam K Laufer
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, USA
    J Infect Dis 193:872-8. 2006
    ..Human immunodeficiency virus (HIV) infection and malaria coexist in much of Africa. Previous studies differ in their findings on the interactions between the 2 infections...
  10. pmc Clinical manifestations of new versus recrudescent malaria infections following anti-malarial drug treatment
    Ayesha M Shaukat
    Malaria Group, Howard Hughes Medical Institute Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    Malar J 11:207. 2012
    ..The clinical benefit of preventing new infections has never been compared to that of curing the initial infection...
  11. ncbi request reprint Observational cohort study of HIV-infected African children
    Miriam K Laufer
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    Pediatr Infect Dis J 25:623-7. 2006
    ..Children identified through voluntary counseling and testing (VCT) represent a unique cohort that has not been previously described in the literature...
  12. ncbi request reprint Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies
    Miriam K Laufer
    Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, 685 W Baltimore Street, HSF 1 480, Baltimore, MD 21201, USA
    Drug Resist Updat 7:279-88. 2004
    ..The finding that drug resistance decreases with the removal of drug pressure could provide a new paradigm for malaria treatment policies in Africa...
  13. pmc Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data
    Anne E P Frosch
    Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD, USA
    Malar J 10:116. 2011
    ..This observation suggests that there is continuing use of ineffective anti-malarials in Africa and that persistent chloroquine-resistant malaria is due to ongoing drug pressure despite national policy changes...
  14. pmc Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations
    Mark A Travassos
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Pediatr Res 65:64R-70R. 2009
    ..The emergence and spread of resistance also results from an interplay of these factors. Current efforts to characterize and deter resistance to new combination therapy are also discussed...
  15. ncbi request reprint Cotrimoxazole prophylaxis and malaria in Africa: Have the important questions been answered?
    Miriam K Laufer
    Am J Trop Med Hyg 75:373-4. 2006
  16. ncbi request reprint A community-based study of the incidence of trimethoprim-sulfamethoxazole-preventable infections in Malawian adults living with HIV
    Joep J G van Oosterhout
    Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi
    J Acquir Immune Defic Syndr 39:626-31. 2005
    ..These should also assess benefit in patients receiving antiretroviral therapy...
  17. pmc Pneumocystis pneumonia in HIV-positive adults, Malawi
    Joep J G van Oosterhout
    University of Malawi College of Medicine, Blantyre, Malawi
    Emerg Infect Dis 13:325-8. 2007
    ..PcP incidence was highest in patients with the lowest CD4 counts, but PcP is uncommon compared with incidences of pulmonary tuberculosis and bacterial pneumonia...

Research Grants3

  1. Molecular epidemiology of drug resistant malaria
    MIRIAM LAUFER; Fiscal Year: 2007
    ..abstract_text> ..